晚期非小细胞肺癌的免疫治疗研究进展  

Research progress in immunotherapy of advanced non-small cell lung cancer

作　　者：林凌[1] 陈振岗[1] 赵鸿杰 张民 LIN Ling;CHEN Zhen-gang;ZHAO Hong-jie;ZHANG Min(Department of Oncology,Tianjin Baodi District People's Hospital,Tianjin 301800,China)

机构地区：[1]天津市宝坻区人民医院肿瘤科,天津301800

出　　处：《中国城乡企业卫生》2023年第11期28-30,共3页Chinese Journal of Urban and Rural Enterprise Hygiene

摘　　要：免疫治疗是一种常用的治疗方式,在现阶段临床研究中发现,免疫治疗的优势比较明显。相关研究显示,免疫治疗可以作为治疗癌症的第4种方法,其他3种是手术疗法、放射疗法和化学疗法,免疫治疗对患者自身病情干预有重要作用。非小细胞肺癌约占所有肺癌的80%,约75%的患者发现时已处于中晚期。在晚期非小细胞肺癌患者治疗过程中,应用免疫治疗的优势明显,为改善患者自身病情提供了帮助。免疫治疗可以通过调动机体免疫系统杀灭肿瘤细胞,能改善晚期非小细胞肺癌的治疗效果。鉴于此,本文对晚期非小细胞肺癌的免疫治疗研究进展进行了综述,力图能够为晚期非小细胞肺癌患者实施免疫治疗提供参考。Immunotherapy is one of the commonly used treatment methods.In the present clinical research,it is found that the advantages of immunotherapy are obvious.Related studies have shown that immunotherapy can serve as the fourth method for treating cancer,with the other three being surgical therapy,radiation therapy,and chemotherapy.Immunotherapy plays an important role in intervening with patients'own conditions.Non-small cell lung cancer accounts for about 80%of all lung cancers,and about 75%of patients are already in the middle to late stage when discovered.In the treatment process of advanced non-small cell lung cancer patients,the application of immunotherapy has obvious advantages,providing help for improving the patient's own condition.Immunotherapy can improve the therapeutic effect of advanced non-small cell lung cancer by mobilizing the body's immune system to kill tumor cells.In view of this,this article reviews the progress of immunotherapy research on advanced non-small cell lung cancer,aiming to provide reference for the implementation of immunotherapy in patients with advanced non-small cell lung cancer.

关 键 词：晚期非小细胞肺癌 免疫治疗 研究现状 

分 类 号：R979.1[医药卫生—药品]